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Abstract
Background: The adverse reactions (ADRs) of targeted therapy were closely associated with treatment response,
clinical outcome, quality of life (QoL) of patients with cancer. However, few studies presented the correlation
between ADRs of targeted therapy and treatment effects among cancer patients. This study was to explore the
characteristics of ADRs with targeted therapy and the prognosis of cancer patients based on the clinical data.
Methods: A retrospective secondary data analysis was conducted within an ADR data set including 2703 patients
with targeted therapy from three Henan medical centers of China between January 2018 and December 2019. The
significance was evaluated with chi-square test between groups with or without ADRs. Univariate and multivariate
logistic regression with backward stepwise method were applied to assess the difference of pathological
characteristics in patients with cancer. Using the univariate Cox regression method, the actuarial probability of
overall survival was performed to compare the clinical outcomes between these two groups.
Results: A total of 485 patients were enrolled in this study. Of all patients, 61.0% (n = 296) occurred ADRs including
skin damage, fatigue, mucosal damage, hypertension and gastrointestinal discomfort as the top 5 complications
during the target therapy. And 62.1% of ADRs were mild to moderate, more than half of the ADRs occurred within
one month, 68.6% ADRs lasted more than one month. Older patients (P = 0.022) and patients with lower education
level (P = 0.036), more than 2 comorbidities (P = 0.021), longer medication time (P = 0.022), drug combination (P =
0.033) and intravenous administration (P = 0.019) were more likely to have ADRs. Those with ADRs were more likely
to stop taking (P = 0.000), change (P = 0.000), adjust (P = 0.000), or not take the medicine on time (P = 0.000). The
number of patients with recurrence (P = 0.000) and metastasis (P = 0.006) were statistically significant difference
between ADRs and non-ADRs group. And the patients were significantly poor prognosis in ADRs groups compared
with non-ADRs group.
Conclusion: The high incidence of ADRs would affect the treatment and prognosis of patients with cancer. We
should pay more attention to these ADRs and develop effective management strategies.
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Background
According to the latest global cancer data report, there
are approximately 18.1 million new cancer cases in the
world in 2018 [1]. In China, a total of 3.299 million
people had been diagnosed as cancer in 2015, with an
average of more than 10 thousand people per day. Thus,
cancer has emerged as a worldwide health problem [2].
A study showed the 5-year overall survival rate of pa-
tients with advanced cancer is only 2% ~ 27% following
traditional treatment methods such as chemotherapy
and radiotherapy [3]. It is difficult to further improve
the treatment efficacy of traditional treatment due to the
limitations caused by toxicity and ADR [4]. Precision
medicine fully considers the individual variability and
differences among patients’ treatment strategies. With
the development of bioinformatics technology, we could
classify some cancers based on their specific molecular
expressions. These advances have further allowed the
identification of molecular therapeutic targets specific to
cancer cells, thus providing a framework whereby ther-
apies can be specifically matched to corresponding mo-
lecular targets [5]. By targeting the complex network of
signaling pathways that regulates cell proliferation,
angiogenesis, and apoptosis (cell death), researchers have
developed new targeted agents that interfere with the
growth and proliferation of cancer cells [6].
Several studies showed that the targeted therapy could
improve the overall survival (OS), progression-free sur-
vival (PFS), and response rate (RR) of cancer patients [7,
8]. Moreover, compared with chemotherapy, targeted
therapy has lower toxicity, better tolerance and reduced
hospitalization time [9]. Although the lethal ADR is
lower than chemotherapy, targeted drugs need to be
used for extended periods or even indefinitely, which
produce the high incidence (80%) for some ADRs in the
process of targeted therapy [10]. The main characteris-
tics of the ADR from targeted therapies are as follows:
1) they occurred in multiple organ systems; 2) different
ADRs were within different targeted drugs (in terms of
types, frequency and severity); 3) most of them occurred
in the early stage and would not aggravate with the pro-
gress of treatment; 4) most of them were mild and could
be controlled effectively; 5) Some of them were intoler-
able to patients required for discontinuation or other in-
terventions. Therefore, it is very important to control
the ADRs to achieve optimal clinical medication and
benefit the prognosis of patients with cancer [11].
According to a recent study, the incidence of ADRs
dominated in skin and mucous were as high as 86.4%
during the targeted therapy [12]. Other ARDs include
gastrointestinal reactions, hypertension, coagulation
disorders and cardiotoxicity, which produced poor com-
pliance correlated with the negative impact on the QoL
and daily activity of patients with cancers [13]. Some
studies showed that about 32% of patients with targeted
molecular treatment had to discontinued the plan due to
ADRs, which led to poor prognosis including cancer re-
currence or progression [14]. Overall, it is imperative to
focus on the ADRs of targeted therapies to improve the
treatment response and the QoL. To this end, we should
not only deal with the common ADRs but also be alert
to the difficult ones [15]. However, there are few studies
associated with ADRs of targeted cancer therapy now.
And most of the published studies did not investigate
other characteristics such as time and duration of ADRs
of the treated cancer therapy-related ADRs [16]. More-
over, few studies explored the correlation between ADRs
and prognosis of patients with cancers, and on the situ-
ation of targeted drug treatment [17].
To provide effective identification and evaluation for
ADRs, this study which guided by the theory of symp-
tom experience model (SEM) [18] was designed to de-
scribe the incidence and characteristics of ADRs in
cancer patients with targeted therapies and to investigate
clinical outcomes associated with ADRs based on clinical
data retrospectively. The SEM provide a complete defin-
ition of symptom experience, including antecedents,
symptom experience, process and result. The main con-
tent of the model is symptom, and the symptom experi-
ence has four aspects, including the perception of
symptom frequency, intensity, perplexity and symptom
meaning; the influencing factors (antecedents) contain
demographic characteristics, disease characteristics and
individual characteristics. Outcome indicators are the re-
sults of symptom experience, including adjustment to ill-
ness, QoL, mode, functional status, disease progression
and survival. And then we chose some variables from 3
modules of demographic characteristics, disease charac-
teristics and individual characteristics in this theory and
explore whether these variables are influencing factors of
ADRs. Meanwhile, we described the symptom experi-
ence of ADRs caused by targeted therapy including
ADRs intensity, frequency and meaning. Finally, we
chose outcome indicators according to the consequences
of SEM (Fig. 1).
We aim to describe the actual situation and ADR of
targeted therapies in cancer patients. We also aim to
understand the impact of ADR on patients, then to pro-
vide basis for clinical workers to effectively identify and
accurately evaluate ADR and carry out targeted interven-
tion measures.
Methods
Study design, setting and samples
A retrospective cohort design was selected for analysis
with prospective data collected from electronic medical
records (EMRs) between Jan 2108 and Dec 2019 by
three nurses in the oncology department of three
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hospitals in Henan, China. The samples were non-
probabilistic selection. Patients’ records were included in
the analysis if they (1) were diagnosed with cancer be-
tween January 2017 and December 2017; (2) were cancer
patients with targeted therapy and (3) were more than
18 years old. The informed consent was not required by
using the de-identified and administrative data. The
sample size was determined with the time, setting and
type of patients reviewed. The sample frame was refined
to include 1897 clients.
Population selection and data variables
Medical and nursing records were excluded if they were
incomplete or without complete ADRs records. ADRs
are harmful and irrelevant reactions when normal dose
drugs are used to prevent, diagnose, treat diseases or
regulate physiological functions [6]. According to inten-
sity, ADR can be divided into three levels of mild (ADR
that the subject tolerates well, causes minimal discom-
fort and does not interfere with daily activities), moder-
ate (ADR that are bothersome enough to interfere with
Fig. 1 Framework of research
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the normal execution of daily activities) and severe
(ADR that do not allow daily activities) [19]. We identi-
fied these ADRs caused by targeted drugs based on the
events that these ADRs began to appear with the appli-
cation of targeted drugs, and decreased or disappeared
when these drugs were reduced or stopped. Moreover,
according to the ADR / Event Association Evaluation
Criteria in the guidelines for the use of ADRs terms, the
reports with “possibly unrelated” and “unable to be eval-
uated” were excluded. Finally, a total of 485 patients
were analyzed and only 296 patients were with an in-
cluded code for ADRs. Then we examined the following
areas: patients’ socio-demographic characteristics (age,
gender, education level, place of residence, family
income, medical insurance); disease characteristics (pri-
mary cancer, disease stage and type, drug use, comorbid-
ities: calculated as the number of chronic diseases
included in the Charlson Comorbidity Index (CCI)),
ADRs (type, intensity, start time, duration); treatment
compliance (discontinuing medication, change medica-
tion, dose adjustment, take medicine on time); disease
progression (recurrence, metastasis) and overall survival.
Data collection
The de-identified EMRs data was collected by nursing
staffs working in the oncology departments in three hos-
pitals and three graduate nursing students in Zhengzhou
university. One student extensively involved in the ADRs
study trained the other two students to extract data.
Interrater reliability was 98% ~ 100% between the trainer
and the other two students. The data, collected from
medical and nursing records and consent documents,
was coded anonymously according to Preferred terms
(PT) of Medical Dictionary for Regulatory Activities
(MedDRA)) [20]. The patients were divided into ADR
group and none-ADR group according to whether they
had an ADR or not.
Statistical analysis
Data were entered into the SPSS version 21 (IBM,
Armonk, NY, USA) for descriptive analysis. Continuous
data were presented as mean and standard deviations or
as medians and interquartile ranges, categorical variables
were shown as proportions with 95% confidence inter-
vals. In this matched study, the descriptive statistics for
the two broad groups were displayed. The statistical
significance of difference between two groups was evalu-
ated with chi-square test. And univariate and multivari-
ate logistic regression with backward stepwise selection
were performed to examine any differences in the char-
acteristics of cancer patients with undergoing targeted
therapy using a dichotomous outcome representing pa-
tients with ADRs or not. Logistic regression models were
developed with the dependent variable of ADRs. The
univariate Cox regression were selected for univariate
survival analysis between two groups. The independent
variables of interest were the other variables available in
the EMRs.
Results
Sociodemographics of patients enrolled into this study
A total of 1897 patients were selected for this study, but
1412 patients were excluded based on the screen criteria.
Finally, a total of 485 patients were enrolled into this
study for further analysis (Fig. 2). The socio-
demographic characteristics of these samples were
shown in Table 1. About 61.0% of the patients were with
ADRs. We could find that the number of patients with
and without ADRs was significantly different among
lung, gastric and colorectal cancer patients (P = 0.008,
0.007 and 0.006, respectively).
Clinical factors associated with ADRs
Multivariate logistic regression was performed to exam-
ine ADR-related factors. The univariate comparison
showed that old age (OR = 1.769, P = 0.019), high edu-
cation level (OR = 0.724, P = 0.017), CCI > 2 (OR =
1.715, P = 0.003), duration of treatment> 3 months
(OR = 1.694, P = 0.004), combined treatment (OR =
1.488, P = 0.028) and route of administration (OR =
1.652, P = 0.034) displayed significant correlation with
ADRs (Table 2). Furthermore, we could find that pa-
tients with older age, lower education level, CCI > 2, the
treatment lasting more than three months, combination
of medicine and intravenous administration showed
significantly more ADRs. Therefore, we inferred that
age, education level, comorbidities, duration of medi-
cine, combination of medicine and route of administra-
tion were independent factors for ADRs by multivariate
logistic regression.
Characteristics of ADRs in the targeted treatment
Of the patients with ADRs, a total of 646 patients had
more than one kind of ADRs (Table 3). In this table, we
could identify a total of 13 ADRs and discovered the top
3 ADRs as skin accessories, fatigue and mucosal damage.
Meanwhile, we also found that most of ADRs appeared
at the early stage of the targeted treatment (≤ 3months,
92.4%), and most of the duration of ADRs was less than
3 months (71.8%). For the ADRs grading, the dominated
patients were with less than Grade III (84.2%). Generally,
we could figure out the overall characteristics of ADRs
from this analysis, which was important for clinical
prevention.
Treatment compliance correlated with ADRs
In order to investigate the compliance of patients with
targeted treatment, we analyzed 5 clinical events
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(discontinuing medication, change medication, adjust
drug dosage, not taking the medication on time) be-
tween two groups with or without ADRs. As a result, we
discovered that patients with cancer were more likely to
occur worse treatment compliance in the ADR group
than those in non-ADR group (all P < 0.05, Table 4).
The number of patients of discontinuing medication,
changing medication, adjust drug dosage, not taking the
medication on time were statistically significant differ-
ence between ADR and non-ADR group. And 33% (98/
296), 53% (157/296) and 62.8% (186/296) of patients in
ADR group changed, adjusted and did not taking the
medication on time, respectively.
Furthermore, we performed univariate Cox regression
to compare the different probability of recurrence, me-
tastasis and overall survival between the two groups with
and without ADRs (Figs. 3, 4, 5). The result showed that
the number of patients of recurrence (P = 0.000) and
metastasis (P = 0.006) were statistically significant differ-
ence between ADR and non-ADR group. Compared
with patients with ADRs, the risk of recurrence (HR =
0.539, 95%CI: 0.393–0.739) and metastasis (HR = 0.650,
95%CI: 0.478–0.885) in patients without ADRs was
lower than that in patients with ADRs. However, there
was no statistical significance for overall survival be-
tween these two groups (P = 0.365, Table 5). All the re-
sults above suggested that cancer patients with ADRs
would occur treatment compliance and produce poor
prognosis.
Discussion
According to this study, patients with ADRs had
different socio-demographic characteristics, treatment
compliance, disease progression and overall survival
compared to those without ADRs. Our study expanded
on previous studies by providing a comprehensive evalu-
ation on pathological characteristics related to ADRs in
patients with targeted therapies. To our knowledge, few
studies had examined the features of ADRs of targeted
cancer therapies [21]. Previous studies only investigated
the type and intensity of ADRs but the occurrence time
and duration of ADRs [13, 22]. In addition, no study re-
ported outcomes related to ADRs and impacts on pa-
tients in China. Through this research, we discovered
some clinical characteristics such as age, education level
and comorbidities and some treatment strategies includ-
ing combinatorial treatment and administration route
were associated with ADRs. Meanwhile, we summarized
more comprehensive characteristics of ADRs, including
the types, grading, occurrence time and duration, which
made up for the incomplete evaluation and analysis of
ADRs. Patients with ADRs had poor treatment compli-
ance, and experienced a higher rate of discontinuation,
change and adjustment of medication, and tended to not
taking medicine on time. Moreover, patients with ADRs
had higher rates of cancer recurrence and metastasis.
In this study, 61% patients with a targeted therapy oc-
curred ADRs, which was lower than previous observa-
tions [23, 24]. In fact, the proportion of patients with
ADRs might be far more than 61%. This is because that
in this study, we excluded patients with incomplete
ADRs information in their medical records, and actually,
there were patients who had ADRs, but their ADRs in-
formation was not recorded regularly. We observed that
there were differences in the number of patients with or
without ADRs in some cancer types, however, this result
Fig. 2 The flowchart of patient enrollment and exclusion
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had no practical significance. Because patients took in
different drugs, the characteristics of ADRs were not the
same. On the other side, as for patients with different
types of cancer had different conditions, complications
and prognosis which might impact on the ADRs. This
study also showed that age and comorbidities were
positive influence on ADRs, and older patients and pa-
tients with more comorbidities were more likely to pro-
duce ADRs which was consistent with the conclusion
from Tristan and Daud et al. [4, 25]. It might be correl-
ation with the decrease of drug metabolism or the dam-
age of liver and kidney function in the elderly.
Table 1 Demographic and disease-related characteristics among patients with or without ADRs (univariate logistic regression)
Characteristics Cases, n
(%)
ADR OR a (95%CI) P value
With, (%) Without, n (%)
All 485 (100) 296 (61.0) 189 (39.0)
Age: Mean (SD) 63.4 (11.8) 67.8 (12.6) 59.5 (11.3)
Age ≥60 294 (60.6) 202 (68.2) 92 (48.7) 3.247 [1.564–7.681] 0.014*
<60 191 (39.4) 94 (31.8) 97 (51.3) 1
Sex Male 261 (53.8) 161 (54.4) 100 (52.9) 1.014 [0.386–1.714] 0.325
Female 224 (46.2) 135 (45.6) 89 (47.1) 1
Education Level College and above 155 (32) 77 (26) 78 (41.3) 0.713 [0.431–0.950] 0.017*
High school and below 330 (68) 219 (74) 111 (58.7) 1
Place of residence Urban 194 (40) 114 (38.5) 80 (42.3) 2.192 [0.689–5.237] 0.189
Rural 291 (60) 182 (61.5) 109 (57.7) 1
Family income (Yuan)/M >10,000 56 (11.5) 35 (11.8) 21 (11.1) 1.885 [0.332–6.457] 0.846
5001 ~ 10,000 227 (46.8) 133 (44.9) 94 (49.7) 0.912 [0.420–1.518] 0.092
3001 ~ 5000 175 (36.1) 113 (38.2) 62 (32.8) 3.817 [0.774–9.220] 0.332
<3000 27 (5.6) 15 (5.1) 12 (6.3) 1
Primary cancer Lung 122 (25.2) 88 (29.7) 34 (18) 3.892 [1.521–10.109] 0.008**
Renal 86 (17.7) 59 (19.9) 27 (14.3) 1.732 [0.458–6.256] 0.122
Gastric 49 (10.1) 22 (7.4) 27 (14.3) 3.069 [1.746–9.961] 0.007**
Colorectal 53 (11) 23 (7.8) 30 (15.9) 3.549 [1.472–9.135] 0.006**
Breast 89 (18.4) 59 (19.9) 30 (15.9) 1.776 [0.753–3.158] 0.084
Non-Hodgkin’s Lymphoma 56 (11.5) 34 (11.6) 22 (11.6) 4.711 [0.843–7.953] 0.569
Others 30 (6.2) 11 (3.7) 19 (10) 1
Medical insurance Yes 383 (79) 231 (78) 152 (80.4) 3.791 [0.654–7.824] 0.264
No 102 (21) 65 (22) 37 (19.6) 1
CCI >2 240 (49.5) 178 (60.1) 62 (32.8) 4.139 [1.418–7.027] 0.003**
≤2 245 (50.5) 118 (39.9) 127 (67.2) 1
Duration of medicine ≤3 months 262 (54) 98 (33.1) 164 (62.1) 0.647 [0.463–0.815] 0.004**
>3months 223 (46) 198 (66.9) 25 (37.9) 1
Combination of medicine Yes 286 (59) 201 (67.9) 85 (45) 1.736 [1.486–4.153] 0.028*
No 199 (41) 95 (32.1) 104 (55) 1
Route of administration Intravenous 209 (43.1) 164 (55.4) 45 (23.8) 3.128 [2.066–7.550] 0.007**
Oral 179 (36.9) 100 (33.8) 79 (41.8) 1.806 [0.538–6.872] 0.075
Subcutaneous 65 (13.4) 25 (8.4) 40 (21.2) 1.257 [0.296–1.836] 0.066
Intrathecal 7 (1.4) 3 (1.0) 4 (2.1) 2.129 [0.588–4.967] 0.125
Intraperitoneal 25 (5.2) 4 (1.4) 21 (1.1) 1
Abbreviations: ADR, adverse reactions; CCI, Charlson Comorbidity Index
# Unmarried = single, divorced, and widow;
* P values are statistically significant
a Binary logistic regression models were computed for each characteristic separately and the ADR was included as an independent variable
*P<0.05, **P<0.01
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Additionally, comorbidities led patients to suffer from
complicated conditions, which might also stem from
using a number of medications correlated with the
ADRs caused by drug interaction. Furthermore, the
interaction between diseases might produce worse phys-
ical, emotional and social function [26].
Especially, this study highlighted the importance of
health education. We concluded that the education level
of patients affected the occurrence of ADRs. When the
underlying reasons were investigated, it was found that
patients with low education level could not understand
the targeted therapies, and therefore could not accept
the health information related to drug use smoothly.
This research showed that more than 90% of patients
undergoing targeted therapy, which indicated that it was
necessary to know drug-related knowledge and to solve
ADRs through health education by medical staffs [27].
Therefore, medical staffs should pay more attention to
elderly patients or patients with more comorbidities. We
should know and monitor the disease changes, treatment
strategies, drug efficacy and medication of elderly and
comorbid patients. What’s more, it is very important to
strengthen early assessment and risk management,
which are of great significance to improve drug response
and reduce ADRs. At the same time, we also suggest
guiding the elderly and comorbid patients to carry out
self-management, and to remind and supervise patients
to implement ADRs management. By the effective health
education, we could improve the understanding of tar-
geted therapies and the ADRs of these patients, allowing
them the ability to become familiar with the drugs they
used [28]. We should also teach patients to record utiliz-
ing medication diaries and assist patients into managing
comorbidities, in order to balance the application
Table 2 Demographic and disease-related characteristics for predicting ADRs (multivariate logistic regression)
Factors a B estimates OR 95% CI P value
Age≥ 60 0.842 1.769 1.248–1.728 0.022*
Education level (High school and below) −0.624 0.724 0.576–0.962 0.036*
CCI (> 2) 0.910 1.715 1.021–1.824 0.021*
Duration of medicine (> 3 months) 0.766 1.694 1.094–1.743 0.022*
Combination of medicine (yes) 0.734 1.488 1.427–1.655 0.033*
Route of administration (Intravenous) 0.689 1.652 1.468–3.935 0.019*
(multivariate logistic regression)
Abbreviations: ADR adverse reactions, CCI Charlson Comorbidity Index, OR Odds ratio, CI Confidence interval;
a The reference categories were age, education level, CCI, duration of medicine, combined treatment and route of administration respectively
*P<0.05
Table 3 Characteristics of ADRs
Characteristics Frequency % Characteristics Frequency %
Type of ADR ADR grading
Skin and its accessories 125 19.3 Grade I 248 38.4
Fatigue 109 16.9 Grade II 153 23.7
Mucosal damage 94 14.6 Grade III 143 22.1
HBP 76 11.8 Grade IV 70 10.8
Gastrointestinal discomfort 69 10.7 Grade V 32 5.0
Insomnia 59 9.1 Duration
Hand-foot syndrome 45 7.0 <1 M 31.4
Cardiotoxicity 24 3.7 1 M~ 40.4
Hematological system disorders 23 3.6 3 M~ 21.2
Thrombus 8 1.2 6 M~ 7.0
Interstitial pneumonia 4 0.6
Others 10 1.5
The start time of ADR
<1M 333 51.5
1 M~ 264 40.9
3 M~ 49 7.6
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between other drugs and targeted drugs. Moreover, we
should try to prevent the ADRs of targeted therapies in
advance, visit patients before targeted treatment to
evaluate and review patients, then discuss with patients
to develop educational goals and plans to facilitate ADRs
prevention.
Combined treatment and route of drug administration
may affect the ADR of targeted therapies, which has
been confirmed by Staats, Jui-Chun, and Bhullar et al.,
and is consistent with our research [6, 29, 30]. As re-
ported previously by Muro [21], this study indicated that
the duration of drug administration didn’t affect the
ADRs of targeted therapy. The ADRs of drugs were
mostly caused by the components of the drugs them-
selves. Although the toxicity of these drugs didn’t change
over time, some toxicity appeared earlier while some
later. After intravenous administration, drugs rapidly
distributed to the whole body. Drugs without metab-
olism and detoxification could not only kill tumor
cells but also damage normal tissues and organs [31],
thus causing ADRs in multiple systems / organs.
When various drugs were combined in the clinical
treatment, the physicochemical properties, drug reac-
tions, metabolism and excretion may interfere with
each other. At the same time, the accumulation of
toxic components in the body increased the possibil-
ity of ADRs [32]. Therefore, it is necessary to formu-
late reasonable drug treatment strategies, enhance the
awareness of rational drug use, and closely monitor
the drug administration and use.
Table 4 The difference of treatment compliance between ADR and non-ADR group
Variables/group ADR group (n = 296)% Non-ADR group (n = 189)% χ2 P value
Discontinuing medication 184 (62.2) 68 (36) 31.68 0.000
Change medication 49 (16.6) 11 (5.8) 12.26 0.000
Adjust drug dosage 157 (53) 27 (14.3) 73.58 0.000
Not taking the medication on time 110 (37.2) 36 (19) 17.99 0.000
Fig. 3 Recurrence survival curve between patients with and without ADRs
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We also discovered that the top five ADRs in this
study were damage to the skin, fatigue, mucosal damage,
hypertension and gastrointestinal discomfort. Most of
the ADRs of targeted therapy were chronic [17], we
found more than half of the ADRs occurred within 1
month. However, there were also some ADRs such as
cardiotoxicity, which occurred immediately after admin-
istration. A few ADRs such as thrombosis and interstitial
pneumonia may appear after 3 months of administra-
tion. For the most common ADRs of skin, 60% of the
patients had skin ADRs within 1 month after treatment.
Among them, acneiform eruptions appeared in the first
2 weeks of treatment, 46.5% of patients had dry skin in
the first month, and paronychia was more common after
2 months of treatment. During this study, ADRs was
graded according to the latest CTCAE 5.0 standard is-
sued by the U.S. department of health and human ser-
vices in 2017 [19]. We concluded that 84.2% of ADRs
were mild to moderate in severity, which was consistent
with the view that the degree of ADRs of targeted ther-
apies was lower than that of chemotherapy [33]. The
more severe ADRs included cardiotoxicity, coagulation
dysfunction and interstitial pneumonia, these ADRs were
mostly fatal. Generally, skin ADRs were mild, but severe
rash can also lead to death. Another characteristic of the
ADRs of targeted therapies was that the duration of
ADRs was long. 68.6% ADRs of the patients in the study
lasted for more than 1 month. In addition, most of the
ADRs occurred repeatedly, and pulmonary fibrosis
caused by interstitial pneumonia was even permanent.
As for the impact of ADRs on patients and ADRs re-
lated outcomes, we collected data on treatment, disease
progression and prognosis, including drug use, recur-
rence, metastasis and death. We observed that patients
with ADRs might change treatment programs and drugs,
adjust drug dosage and even discontinue treatment.
Meanwhile, compared with patients without ADRs, pa-
tients in ADRs group with orally administered drugs
stopped taking medication and reduced drug dosage
more due to being unable to tolerate the ADRs. The
compliance of patients with orally targeted drugs de-
creased, while the incidence of missed dosages and not
taking drugs on time increased, this was confirmed by
Sano et al. [34]. Therefore, it is important to manage
ADRs well. In this study, 62.2% of patients stopped tak-
ing drugs and 62.8% did not take drugs on time due to
ADRs. ADRs resulted in negative impact on the QoL,
physical function, daily activity, social and emotional
Fig. 4 Metastasis survival curve between patients with and without ADRs
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function of cancer patients, which reduced the desire of
patients for treatment, affected their work and study, so
as to make patients resist taking medicine [35]. What’s
worse, these patients suffered for a long time, resulting
in the sense of helplessness and apparent social partici-
pation disorder, anxiety and psychological distress, these
were all reasons why it was difficult for patients to carry
out treatment smoothly.
In this study, we used survival analysis to compare the
disease progression and prognosis of patients with and
without ADRs. The rates of patients who had cancer re-
currence or metastasis were 46.6 and 43.1%, a small pro-
portion patients died (13%). We can see, within the time
frame of this review, the proportion of endpoint events
was less than 50%, so we used Cox regression rather
than K-M method for analysis. The results showed
recurrence or metastasis occurred more in patients with
ADRs. Due to the influence of ADRs on physiology and
psychology, patients’ health condition was worse which
reduce the tolerance of patients to resist disease. More-
over, the normal progress of treatment is hindered, and
because of the poor compliance, the drugs did not
achieve the desired effect so that the ability of drugs to
control and treat the disease was declined too, which led
to the recurrence and metastasis of cancer [36]. There-
fore, it is very important to implement ADRs manage-
ment to reduce and alleviate the ADRs in order to
guarantee the treatment process and improve the medi-
cation compliance to prevent patients from stopping, re-
ducing or not taking medicine on time.
Advantages and limitations
Our study supplemented the situation in mainland
China about ADRs of patients who received targeted
therapies. Previous studies only analyzed the type and
classification of ADRs, but we comprehensively inter-
preted the characteristics of ADRs, further discussed the
start time and duration of ADRs, and explored some in-
fluencing factors of ADRs. Moreover, our research was
based on SEM theory, which provided the basis for
Fig. 5 Overall survival analysis between patients with and without ADRs
Table 5 Comparison of disease progress and overall survival
according to ADR group
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determining the research program and the selection of
variables in the research. However, it is necessary to
highlight some limitations. A lot of ADRs information in
the EMRs reviewed in this study were missing or incom-
plete, which indicated that sometimes, there was no
reporting or recording of ADRs in clinical practice, or
there was no standard ADRs records, which leaded to
difficulties in extracting information and means that the
results could be biased. The reasons may be that most of
the ADRs were chronic and not serious, so, medical
staffs were not aware of the importance. It should be
noted that we had reviewed only the last 2 years so that
data collection was limited. However, there was no dif-
ference in the outcome of death between ADR and non-
ADR group, it might require a longer duration to review.
Similarly, although we found differences in recurrence
and metastasis outcomes between the two groups, a
longer-term review could be more meaningful. At the
same time, the impact of ADRs on patients and the
prognosis of the disease also includes the quality of life,
functional status, psychological status, OS and PFS of
patients, more prospective research to explore these in-
dicators are of great significance to clinical practice and
theory.
Implication
This study provided data on ADRs of cancer patients
with targeted treatment, and analyzed the influencing
factors and outcomes of ADRs, which indicated import-
ant information for medical staff, allowing them to pay
more attention to ADRs of targeted treatment of cancer
patients. Meanwhile, the results of this study promoted
the identification, monitoring, evaluation and recording
of ADRs and provided ideas and premise for interven-
tion research of ADRs. Furthermore, we supply a refer-
ence for clinical practice, in order to help and improve
clinical decision-making. Additionally, the results of this
study were of great significance to promote the safety of
patients, and provided the basis for further understand-
ing the ADRs of targeted therapies and the factors that
should be paid attention to during medication adminis-
tration and use. On the other side, health-care providers
should pay attention to the factors identified in this
study and consider the following strategies: 1. Clinical
strategies: principles of coping with ADRs: before treat-
ment: ① Baseline comorbidity assessment and interven-
tion (1) Comprehensively evaluating whether the patient
has some risk factors, balancing the advantages and dis-
advantages of treatment, and developing individualized
treatment plan, (2) Controlling other comorbidities, (3)
Symptomatic treatment; ② Patient education (1) Pa-
tients need to fully understand the disease and treatment
(education on potential ADRs), (2) Psychological educa-
tion; after treatment: ① Close monitoring and treatment
(1) CTCAE standard evaluation, developing standardized
ADRs terms according to the specific national condi-
tions/priorities in China in combination with the
existing international standardized terminology, (2) de-
veloping specific ADRs evaluation plan, determining the
key points of ADRs monitoring and identification, devel-
oping ADRs record form, the usage, dosage, course of
treatment should be strictly monitored, (3) Quality of
life report of patients, (4) providing fast and effective
care in order to minimize the risk and severity of ADRs;
② Rapid ADRs management (1) Standard medical inter-
vention, (2) Considering dose adjustment or interruption
if necessary, (3) Actively coping with complex ADRs in
multidisciplinary team mode, (4) Clinicians and patients
should weigh the potential survival benefits when plan-
ning to change drugs; ③ Making reasonable follow-up
strategy: (1) Following up on time, recording ADRs in
detail, (2) Dynamic comparison of ADRs, finding prob-
lems and taking measures in time. 2. Prevention of com-
mon ADRs ① Skin ADRs: using skin care preparations,
avoiding skin injury behaviors, skin preventive medica-
tion; ② Fatigue: ensuring adequate sleep, developing
individualized exercise program, adhering to the reason-
able intensity of exercise; ③ Mucositis: keeping oral hy-
giene and avoiding irritating diet; ④ HBP: blood
pressure monitoring, controlling blood pressure below
140 / 90 mmHg, drug control; ⑤Gastrointestinal reac-
tions: rational diet and preventive medication. 3. Mea-
sures should be taken for ADR related factors: ① We
should pay more attention to the patients with older age,
low education level and comorbidity, improve the phys-
ical condition of these patients in order to strengthen
tolerance; ② We should formulate rational treatment
strategies, closely monitor the drug use and avoid
unreasonable/dangerous combinations of drugs; ③The
implementation of individualized and effective health
education to improve patients’ cognition to promote
self-management. 4. Prevention and self-management
education for patients and their families①Health educa-
tion includes disease knowledge, drug knowledge and
ADRs knowledge; ② Behavior guidance includes medi-
cation compliance guidance, nutrition guidance and
medication guidance; ③ Skills training includes medica-
tion records, ADR identification and monitoring, ADR
prevention measures, the role and application of trad-
itional Chinese medicine.
Conclusion
The incidence of ADRs in cancer patients during tar-
geted therapy was high, with different features involving
various systems / organs. Most of ADRs were mild to
moderate in severity, while some were lethal. These
ADRs were mostly chronic and occurred after one
month of administration. Some ADRs existed during the
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treatment or even had permanent damage. Age, educa-
tion level, comorbidity and medication strategy could
impact on ADRs, while ADRs could also affect the treat-
ment and prognosis of patients. Therefore, the charac-
teristics, influencing factors and outcomes of ADRs
obtained in this study could accumulate experience for
clinical staff to carry out ADRs management, to improve
the treatment effectiveness and ensure the safety of
patients.
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